Please assess the completion status of the following clinical trial:

Trial Title: Role of Early Versus Late Switch to Lapatinib-Capecitabine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* Women with ErbB2+ MBC (ErbB2 expression confirmed by immunohistochemistry or FISH/CISH, either in the primary tumor or in the metastasis, according to the institution's common practice);~* Older than 18 years old;~* Have received prior treatment with trastuzumab-containing regimen for ErbB2+ breast cancer;~* Progressing after trastuzumab-containing regimen either used for the treatment of metastatic disease or progressing after adjuvant /neoadjuvant trastuzumab treatment;~* Eligible to start standard treatment with Lapatinib-capecitabine at conventional doses, in the community setting;~* Signed consent to participate and release information for this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients on second line treatment (Type: None): Patients treated with Lapatinib-capecitabine immediately after first Trastuzumab-containing regimen progression
- Patients on third or more lines treatment (Type: None): Patients treated with Lapatinib-capecitabine after 2 or more lines of treatment after first Trastuzumab-containing regimen progression

Based on this trial design, predict the completion outcome and termination type (if applicable).